Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT03862716

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03862716
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03862716. Randomized; no masking; primary purpose treatment. Start 2019-04-23 (actual); primary completion 2022-06-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
Acronym
REMITiDegLira
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
IDegLira
Intervention (Drug)
insulin degludec
Intervention (Drug)
Metformin
Intervention (Behavioral)
Lifestyle Therapy
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03862716
Content hash
7ad0d2822a2c69375db7242ca13ab1a3a8ec95e6cb6a631d40f081027de323e3